FindTrial
Sign In

Studying the extra benefits of using Guduchyaamalak kwath with metformin to treat type 2 diabetes

CLINICAL STUDY OF ADD ON EFFECT OF GUDUCHYAAMALAK KWATH ALONG WITH METFORMIN IN THE MANAGEMENT OF PRAMEHA (NIDDM) - Randomised controll trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112043
Enrollment
80
Registered
2026-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Tilak Ayurved Mahavidyalaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group in between 18 60 years, Participants having classical signs and symptoms of prameha as per ayurvedic text, Participants of any gender, religion and socioeconomic status, HbA1C- from 6.5-9% , Participants already on Tablet Metformin 500 mg bd, Blood Sugar level Fasting - 150-250 Post Prandial - 250-450

Exclusion criteria

Exclusion criteria: 1. Known case of type I diabetes mellitus. 2. Participants having other complicated systematic disorders like, diabetic ketoacidosis, nephropathy, heart disease etc. 3. Pregnant women and lactating mothers. 4. Participant on insulin or steroid treatment. 5.Gestational Diabetes.

Design outcomes

Primary

MeasureTime frame
Reduction in Fasting and Post prandial blood sugar levelTimepoint: with gap of every 15days for 3months—

Secondary

MeasureTime frame
Reduction in HbA1c Values and glycemic control in diabetic patientsTimepoint: 90 days—

Countries

India

Contacts

Public ContactVd. Chetan Sudhakar Patil

Tilak Ayurved Mahavidyalaya and Seth Tarachand Ramnath Charitable Ayurvedic Hospital

sangeetap14@gmail.com9130774107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026